Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)

Historical Holders from Q1 2016 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CRVS on Nasdaq
Shares outstanding
74,361,296
Price per share
$7.70
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
41,673,686
Total reported value
$307,002,895
% of total 13F portfolios
0%
Share change
-114,786
Value change
+$4,353,875
Number of holders
101
Price from insider filings
$7.70
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 12% -11% $28,475,581 9,785,423 0% ORBIMED ADVISORS LLC 12 May 2025
MILLER RICHARD A MD 7.7% $15,191,271 5,220,368 Richard A. Miller 31 Dec 2024
BlackRock, Inc. 5.4% $29,594,309 4,015,510 BlackRock, Inc. 30 Sep 2025
As of 30 Sep 2025, Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) has 101 institutional shareholders filing 13F forms. They hold 41,673,686 shares. of 74,361,296 outstanding shares (56%) .

Top 25 institutional shareholders own 53% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 9.6% 7,165,006 0% 1.3% $52,806,094
Point72 Asset Management, L.P. 8.7% 6,454,274 -8.4% 0.1% $47,567,999
BlackRock, Inc. 6.3% 4,710,442 +11% 0% $34,715,958
VANGUARD GROUP INC 4.7% 3,471,925 +5.8% 0% $25,588,088
ADAMS STREET PARTNERS LLC 4.4% 3,275,616 0% 16% $24,141,290
RTW INVESTMENTS, LP 3.6% 2,679,479 0% 0.24% $19,747,760
Vivo Capital, LLC 3% 2,234,566 0% 1.3% $16,468,751
Foresite Capital Management VI LLC 2.3% 1,731,233 0% 4.9% $12,759,187
GEODE CAPITAL MANAGEMENT, LLC 2% 1,456,528 +7% 0% $10,736,839
PERCEPTIVE ADVISORS LLC 1.9% 1,438,595 0% 0.31% $10,602,445
STATE STREET CORP 1.4% 1,006,319 +51% 0% $7,416,571
MORGAN STANLEY 0.83% 617,224 -31% 0% $4,548,941
NORTHERN TRUST CORP 0.63% 466,486 +16% 0% $3,438,001
GOLDMAN SACHS GROUP INC 0.6% 445,670 +162% 0% $3,284,588
SPHERA FUNDS MANAGEMENT LTD. 0.55% 407,709 +123% 0.71% $3,004,815
GSA CAPITAL PARTNERS LLP 0.54% 401,407 +26% 0.25% $2,958,000
BARCLAYS PLC 0.42% 309,152 -10% 0% $2,278,448
TWO SIGMA INVESTMENTS, LP 0.27% 203,360 -9.2% 0% $1,498,763
WELLINGTON MANAGEMENT GROUP LLP 0.24% 180,175 +76% 0% $1,327,889
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.24% 177,788 +9.9% 0% $1,310,298
TOWERVIEW LLC 0.23% 170,000 0% 0.91% $1,252,900
Empirical Financial Services, LLC d.b.a. Empirical Wealth Management 0.23% 169,200 +0.71% 0.03% $1,247,004
UBS Group AG 0.22% 162,074 +81% 0% $1,194,485
TWO SIGMA ADVISERS, LP 0.22% 161,600 -24% 0% $1,190,992
BANK OF AMERICA CORP /DE/ 0.2% 151,966 +14% 0% $1,119,989

Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 20,164 $155,101 +$154,377 $7.70 2
2025 Q3 41,673,686 $307,002,895 +$4,353,875 $7.37 101
2025 Q2 41,781,497 $167,123,225 +$27,178,676 $4.00 92
2025 Q1 36,268,523 $115,333,082 -$7,370,971 $3.18 87
2024 Q4 37,671,901 $201,543,130 +$34,430,538 $5.35 85
2024 Q3 30,026,264 $158,538,176 +$12,733,378 $5.28 64
2024 Q2 27,591,708 $50,216,835 +$17,655,350 $1.82 46
2024 Q1 17,899,766 $31,860,771 -$2,307,354 $1.78 47
2023 Q4 19,183,314 $33,762,501 -$27,312 $1.76 46
2023 Q3 19,186,334 $28,011,450 -$1,230,963 $1.46 52
2023 Q2 19,491,995 $44,633,999 +$735,026 $2.29 51
2023 Q1 20,767,710 $18,897,208 -$163,899 $0.91 35
2022 Q4 21,339,925 $18,137,963 -$596,815 $0.85 37
2022 Q3 22,045,962 $18,043,081 -$3,296,252 $0.82 36
2022 Q2 25,545,319 $25,290,212 -$3,287,602 $0.99 37
2022 Q1 27,372,071 $44,888,000 -$1,208,549 $1.64 49
2021 Q4 27,678,421 $66,701,000 -$7,830,824 $2.41 58
2021 Q3 28,180,541 $136,389,000 +$22,763,799 $4.84 56
2021 Q2 23,673,230 $63,207,000 +$8,569,511 $2.67 44
2021 Q1 20,394,379 $62,810,000 +$12,095,864 $3.08 47
2020 Q4 16,311,910 $58,071,014 -$3,250,968 $3.56 34
2020 Q3 16,610,724 $66,606,016 -$11,812,621 $4.01 32
2020 Q2 20,440,072 $55,596,011 -$392,226 $2.72 33
2020 Q1 20,651,240 $43,573,167 -$3,308,940 $2.11 36
2019 Q4 20,779,789 $113,038,430 -$10,373,883 $5.44 35
2019 Q3 22,891,685 $68,903,436 -$4,060,897 $3.01 34
2019 Q2 24,342,578 $90,952,754 -$1,478,177 $3.74 43
2019 Q1 24,576,032 $98,778,635 -$918,364 $4.02 55
2018 Q4 25,129,562 $92,162,767 -$2,053,007 $3.67 59
2018 Q3 25,454,371 $218,398,586 -$3,359,100 $8.58 57
2018 Q2 25,906,783 $284,453,314 +$902,957 $10.98 55
2018 Q1 25,285,471 $287,757,705 +$90,628,274 $11.53 53
2017 Q4 16,748,990 $173,521,571 -$6,130,860 $10.36 52
2017 Q3 17,541,888 $279,680,086 +$1,086,255 $15.94 51
2017 Q2 17,495,646 $211,696,598 -$2,854,069 $12.10 47
2017 Q1 17,335,240 $360,050,125 +$9,744,519 $20.77 52
2016 Q4 17,484,501 $250,048,615 +$17,391,580 $14.30 53
2016 Q3 16,266,787 $267,555,203 -$17,040,529 $16.45 44
2016 Q2 14,645,573 $208,464,147 +$14,498,682 $14.26 43
2016 Q1 13,758,120 $198,361,725 +$196,693,691 $14.50 31